Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study.

Humans COVID-19 / epidemiology COVID-19 Vaccines Case-Control Studies Prospective Studies Vaccine Efficacy Germany / epidemiology
COVID-19 Case-control study Hospitalization Omicron SARS-CoV-2 Vaccine effectiveness

Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 20 12 2022
accepted: 22 02 2023
medline: 19 7 2023
pubmed: 14 3 2023
entrez: 13 3 2023
Statut: ppublish

Résumé

COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12-78%), 81.5% (95% CI: 68-90%) and 95.6% (95%CI: 88-99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.

Identifiants

DOI: 10.1007/s15010-023-02012-z PMID: 36913112 PMC: PMC10009838
pubmed: 36913112
doi: 10.1007/s15010-023-02012-z
pii: 10.1007/s15010-023-02012-z
pmc: PMC10009838
doi:

Substances chimiques

COVID-19 Vaccines 0

Banques de données

DRKS
['DRKS00025004']

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1093-1102

Informations de copyright

© 2023. The Author(s).

Références

WHO Dashboard. (2022). https://covid19.who.int/ . Accessed 31.8.2022 2022.
Robert-Koch-Institute. Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). (2022). https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenberichte_Tab.html . Accessed.
Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW. Susceptibility of SARS-CoV-2 Omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 2022;10:e0092622. https://doi.org/10.1128/spectrum.00926-22 .
doi: 10.1128/spectrum.00926-22 pubmed: 35700134
Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e2228008. https://doi.org/10.1001/jamanetworkopen.2022.28008 .
doi: 10.1001/jamanetworkopen.2022.28008 pubmed: 35994285 pmcid: 9396366
Shuai H, Chan JF, Hu B, Chai Y, Yuen TT, Yin F, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603:693–9. https://doi.org/10.1038/s41586-022-04442-5 .
doi: 10.1038/s41586-022-04442-5 pubmed: 35062016
Hui KPY, Ng KC, Ho JCW, Yeung HW, Ching RHH, Gu H, et al. Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract. EBioMedicine. 2022;83:104232. https://doi.org/10.1016/j.ebiom.2022.104232 .
doi: 10.1016/j.ebiom.2022.104232 pubmed: 35988466 pmcid: 9387351
Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603:687–92. https://doi.org/10.1038/s41586-022-04441-6 .
doi: 10.1038/s41586-022-04441-6 pubmed: 35062015 pmcid: 8942849
Chan JF, Hu B, Chai Y, Shuai H, Liu H, Shi J, et al. Virological features and pathogenicity of SARS-CoV-2 omicron BA.2. Cell Rep Mede. 2022;3:100743. https://doi.org/10.1016/j.xcrm.2022.100743 .
doi: 10.1016/j.xcrm.2022.100743
Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Perriat D, Dörre A, et al. Effectiveness of vaccines in preventing hospitalization due to COVID-19: a multicenter hospital-based case-control study Germany, June 2021 to January 2022 Germany. Vaccine. 2022. https://doi.org/10.1016/j.vaccine.2022.11.065 .
doi: 10.1016/j.vaccine.2022.11.065 pubmed: 36509640 pmcid: 9715487
Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28:202–21. https://doi.org/10.1016/j.cmi.2021.10.005 .
doi: 10.1016/j.cmi.2021.10.005
Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. New Engl J Med. 2022;387:21–34. https://doi.org/10.1056/NEJMoa2203965 .
doi: 10.1056/NEJMoa2203965 pubmed: 35704396
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. COVID-19 vaccine effectiveness against the Omicron (B11529) variant. New Engl J Med. 2022;386:1532–46. https://doi.org/10.1056/NEJMoa2119451 .
doi: 10.1056/NEJMoa2119451 pubmed: 35249272
Michel J, Neumann M, Krause E, Rinner T, Muzeniek T, Grossegesse M, et al. Resource-efficient internally controlled in-house real-time PCR detection of SARS-CoV-2. Virol J. 2021;18:110. https://doi.org/10.1186/s12985-021-01559-3 .
doi: 10.1186/s12985-021-01559-3 pubmed: 34078394 pmcid: 8170437
Brinkmann A, Ulm SL, Uddin S, Förster S, Seifert D, Oehme R, et al. AmpliCoV: Rapid whole-genome sequencing using Multiplex PCR amplification and real-time Oxford Nanopore MinION Sequencing Enables Rapid Variant Identification of SARS-CoV-2. Front Microbiol. 2021. https://doi.org/10.3389/fmicb.2021.651151 .
doi: 10.3389/fmicb.2021.651151 pubmed: 34276587 pmcid: 8281033
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8 .
doi: 10.1016/0021-9681(87)90171-8 pubmed: 3558716
Pearce N. Analysis of matched case-control studies. Bmj. 2016;352:i969. https://doi.org/10.1136/bmj.i969 .
doi: 10.1136/bmj.i969 pubmed: 26916049 pmcid: 4770817
Treskova-Schwarzbach M, Haas L, Reda S, Pilic A, Borodova A, Karimi K, et al. Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. BMC Med. 2021;19:212. https://doi.org/10.1186/s12916-021-02058-6 .
doi: 10.1186/s12916-021-02058-6 pubmed: 34446016 pmcid: 8390115
Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance-One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:217–23. https://doi.org/10.1558/mmwr.mm7106e2 .
doi: 10.1558/mmwr.mm7106e2 pubmed: 35143466 pmcid: 8830624
Suzuki K, Ichikawa T, Suzuki S, Tanino Y, Kakinoki Y. Clinical characteristics of the severe acute respiratory syndrome coronavirus 2 omicron variant compared with the delta variant: a retrospective case-control study of 318 outpatients from a single sight institute in Japan. PeerJ. 2022;10:e13762. https://doi.org/10.7717/peerj.13762 .
doi: 10.7717/peerj.13762 pubmed: 35935257 pmcid: 9354737
Leiner J, Pellissier V, Hohenstein S, König S, Schuler E, Möller R, et al. Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals. BMC Infect Dis. 2022;22:802. https://doi.org/10.1186/s12879-022-07781-w .
doi: 10.1186/s12879-022-07781-w pubmed: 36303111 pmcid: 9610359
Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, Valluri SR, Jodar L, McLaughlin JM. BNT162b2 (Pfizer–Biontech) mRNA COVID-19 vaccine against omicron-related hospital and emergency department admission in a large US health system: a test-negative design. SSRN J. 2022. https://doi.org/10.2139/ssrn.4011905 .
doi: 10.2139/ssrn.4011905
Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:255–63. https://doi.org/10.1558/mmwr.mm7107e2 .
doi: 10.1558/mmwr.mm7107e2 pubmed: 35176007 pmcid: 8853475
Šmíd M, Berec L, Přibylová L, Májek O, Pavlík T, Jarkovský J, et al. Protection by vaccines and previous infection against the Omicron variant of severe acute respiratory syndrome coronavirus 2. J Infect Dis. 2022. https://doi.org/10.1093/infdis/jiac161 .
doi: 10.1093/infdis/jiac161 pubmed: 35763416
Shao W, Chen X, Zheng C, Liu H, Wang G, Zhang B, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. Emerg Microbes Infect. 2022;11:2383–92. https://doi.org/10.1080/22221751.2022.2122582 .
doi: 10.1080/22221751.2022.2122582 pubmed: 36069511 pmcid: 9542696
Külper-Schiek W, Piechotta V, Pilic A, Batke M, Dreveton LS, Geurts B, et al. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Front Immunol. 2022;13:940562. https://doi.org/10.3389/fimmu.2022.940562 .
doi: 10.3389/fimmu.2022.940562 pubmed: 36091023 pmcid: 9449804
Zou Y, Huang D, Jiang Q, Guo Y, Chen C. The vaccine efficacy against the SARS-CoV-2 Omicron: a systemic review and meta-analysis. Front Pub Health. 2022. https://doi.org/10.3389/fpubh.2022.940956 .
doi: 10.3389/fpubh.2022.940956
Uk Health Security Agency. COVID-19 vaccine surveillance report - week 35 London, United Kingdom: UK Health Security Agency (2022). Accessed
Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, et al. Case-control vaccine effectiveness studies: data collection, analysis and reporting results. Vaccine. 2017;35:3303–8. https://doi.org/10.1016/j.vaccine.2017.04.035 .
doi: 10.1016/j.vaccine.2017.04.035 pubmed: 28442230 pmcid: 7008029
Verani JR, Baqui AH, Broome CV, Cherian T, Cohen C, Farrar JL, et al. Case-control vaccine effectiveness studies: preparation, design, and enrollment of cases and controls. Vaccine. 2017;35:3295–302. https://doi.org/10.1016/j.vaccine.2017.04.037 .
doi: 10.1016/j.vaccine.2017.04.037 pubmed: 28442231 pmcid: 7007298
Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study. Medrxiv. 2022. https://doi.org/10.1101/2022.04.01.22273281 .
doi: 10.1101/2022.04.01.22273281

Auteurs

Anna Stoliaroff-Pepin (A)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany. Stoliaroff-PepinA@rki.de.

Caroline Peine (C)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0001-6267-3452

Tim Herath (T)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.

Johannes Lachmann (J)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.

Wiebke Hellenbrand (W)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0002-8563-3629

Delphine Perriat (D)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.

Achim Dörre (A)

Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0001-9297-3675

Andreas Nitsche (A)

Centre for Biological Threats and Special Pathogens, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0001-8185-3176

Janine Michel (J)

Centre for Biological Threats and Special Pathogens, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0001-6227-3125

Marica Grossegesse (M)

Centre for Biological Threats and Special Pathogens, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.

Natalie Hofmann (N)

Centre for Biological Threats and Special Pathogens, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.

Thomas Rinner (T)

Centre for Biological Threats and Special Pathogens, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.

Claudia Kohl (C)

Centre for Biological Threats and Special Pathogens, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0002-1480-8911

Annika Brinkmann (A)

Centre for Biological Threats and Special Pathogens, WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0002-9556-4698

Tanja Meyer (T)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0002-4631-0528

Daniel Stern (D)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Berlin, Germany.

Fridolin Treindl (F)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Berlin, Germany.

Brigitte G Dorner (BG)

Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Berlin, Germany.
ORCID: 0000-0002-5100-2546

Sascha Hein (S)

Division Virology, Paul-Ehrlich-Institute, Paul-Ehrlich-Straße 51-59, 63225, Langen, Germany.
ORCID: 0000-0001-7257-4538

Laura Werel (L)

Division Virology, Paul-Ehrlich-Institute, Paul-Ehrlich-Straße 51-59, 63225, Langen, Germany.
ORCID: 0000-0003-2856-8960

Eberhard Hildt (E)

Division Virology, Paul-Ehrlich-Institute, Paul-Ehrlich-Straße 51-59, 63225, Langen, Germany.

Sven Gläser (S)

Klinik für Innere Medizin-Pneumologie und Infektiologie, Vivantes Klinikum Neukölln und Spandau, Berlin, Germany.

Helmut Schühlen (H)

Direktorat Klinische Forschung & Akademische Lehre, Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany.
ORCID: 0000-0001-8630-4264

Caroline Isner (C)

Klinik für Innere Medizin-Infektiologie, Vivantes Auguste-Viktoria-Klinikum, Rubensstr. 125, 12157, Berlin, Germany.

Alexander Peric (A)

Klinik für Pneumologie und Infektiologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249, Berlin, Germany.

Ammar Ghouzi (A)

Schön Klinik Düsseldorf, Interdisziplinäre Notaufnahme, Am Heerdter Krankenhaus 2, 40549, Düsseldorf, Germany.

Annette Reichardt (A)

Helios Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany.

Matthias Janneck (M)

Sektion Nephrologie, Klinik für Kardiologie, Albertinen Krankenhaus, Süntelstraße 11a, 22457, Hamburg, Germany.

Guntram Lock (G)

Klinik für Innere Medizin, Albertinen Krankenhaus, Süntelstraße 11a, 22457, Hamburg, Germany.

Dominik Huster (D)

Klinik für Innere Medizin, Helios Klinikum Erfurt, Erfurt, Germany.

Thomas Grünewald (T)

Klinik für Infektions-und Tropenmedizin, Klinikum Chemnitz, Chemnitz, Germany.
ORCID: 0000-0002-2955-3085

Lars Schaade (L)

Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.

Ole Wichmann (O)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.

Thomas Harder (T)

Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Vaccine effectiveness against severe COVID-19...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Vaccine effectiveness against severe COVID-19...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Vaccine effectiveness against severe COVID-19...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Vaccine effectiveness against severe COVID-19...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Vaccine effectiveness against severe COVID-19...
questionsmedicales.fr › Techniques d'investigation › Développement de vaccin › Efficacité vaccinale › Vaccine effectiveness against severe COVID-19...
questionsmedicales.fr › Régions géographiques › Europe › Allemagne › Vaccine effectiveness against severe COVID-19...